Search

Rocket Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

3.47 4.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.27

Max

3.49

Belangrijke statistieken

By Trading Economics

Inkomsten

171M

123M

EPS

-0.15

Werknemers

202

EBITDA

-1.9M

-47M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+234.43% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3M

397M

Vorige openingsprijs

-0.73

Vorige sluitingsprijs

3.47

Nieuwssentiment

By Acuity

27%

73%

97 / 340 Rangschikking in Healthcare

Rocket Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 22:01 UTC

Rocket Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified. Broader market concerns may be influencing the decline.

13 aug 2026, 19:56 UTC

Rocket Pharmaceuticals Inc shares are lower today, continuing a recent downward trend amid rising U.S. unemployment claims, with no specific company news identified.

12 aug 2026, 19:16 UTC

Rocket Pharmaceuticals Inc shares are lower today, with no specific news driving the decline. Earlier, the stock reached a session high before falling.

11 aug 2026, 20:02 UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

10 aug 2026, 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

8 aug 2026, 00:01 UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

7 aug 2026, 23:01 UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

6 aug 2026, 23:06 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

5 aug 2026, 20:02 UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

4 aug 2026, 19:26 UTC

News
Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

3 aug 2026, 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31 jul 2026, 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30 jul 2026, 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29 jul 2026, 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28 jul 2026, 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27 jul 2026, 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24 jul 2026, 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22 jul 2026, 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20 jul 2026, 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Peer Vergelijking

Prijswijziging

Rocket Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

234.43% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.17 USD  234.43%

Hoogste 15 USD

Laagste 5 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rocket Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Sentiment

By Acuity

97 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat